Cargando…

Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders

OBJECTIVE: To evaluate diabetic retinopathy (DR) screening via deep learning (DL) and trained human graders (HG) in a longitudinal cohort, as case spectrum shifts based on treatment referral and new-onset DR. METHODS: We randomly selected patients with diabetes screened twice, two years apart within...

Descripción completa

Detalles Bibliográficos
Autores principales: Limwattanayingyong, Jirawut, Nganthavee, Variya, Seresirikachorn, Kasem, Singalavanija, Tassapol, Soonthornworasiri, Ngamphol, Ruamviboonsuk, Varis, Rao, Chetan, Raman, Rajiv, Grzybowski, Andrzej, Schaekermann, Mike, Peng, Lily H., Webster, Dale R., Semturs, Christopher, Krause, Jonathan, Sayres, Rory, Hersch, Fred, Tiwari, Richa, Liu, Yun, Ruamviboonsuk, Paisan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758133/
https://www.ncbi.nlm.nih.gov/pubmed/33381600
http://dx.doi.org/10.1155/2020/8839376
_version_ 1783626873871269888
author Limwattanayingyong, Jirawut
Nganthavee, Variya
Seresirikachorn, Kasem
Singalavanija, Tassapol
Soonthornworasiri, Ngamphol
Ruamviboonsuk, Varis
Rao, Chetan
Raman, Rajiv
Grzybowski, Andrzej
Schaekermann, Mike
Peng, Lily H.
Webster, Dale R.
Semturs, Christopher
Krause, Jonathan
Sayres, Rory
Hersch, Fred
Tiwari, Richa
Liu, Yun
Ruamviboonsuk, Paisan
author_facet Limwattanayingyong, Jirawut
Nganthavee, Variya
Seresirikachorn, Kasem
Singalavanija, Tassapol
Soonthornworasiri, Ngamphol
Ruamviboonsuk, Varis
Rao, Chetan
Raman, Rajiv
Grzybowski, Andrzej
Schaekermann, Mike
Peng, Lily H.
Webster, Dale R.
Semturs, Christopher
Krause, Jonathan
Sayres, Rory
Hersch, Fred
Tiwari, Richa
Liu, Yun
Ruamviboonsuk, Paisan
author_sort Limwattanayingyong, Jirawut
collection PubMed
description OBJECTIVE: To evaluate diabetic retinopathy (DR) screening via deep learning (DL) and trained human graders (HG) in a longitudinal cohort, as case spectrum shifts based on treatment referral and new-onset DR. METHODS: We randomly selected patients with diabetes screened twice, two years apart within a nationwide screening program. The reference standard was established via adjudication by retina specialists. Each patient's color fundus photographs were graded, and a patient was considered as having sight-threatening DR (STDR) if the worse eye had severe nonproliferative DR, proliferative DR, or diabetic macular edema. We compared DR screening via two modalities: DL and HG. For each modality, we simulated treatment referral by excluding patients with detected STDR from the second screening using that modality. RESULTS: There were 5,738 patients (12.3% STDR) in the first screening. DL and HG captured different numbers of STDR cases, and after simulated referral and excluding ungradable cases, 4,148 and 4,263 patients remained in the second screening, respectively. The STDR prevalence at the second screening was 5.1% and 6.8% for DL- and HG-based screening, respectively. Along with the prevalence decrease, the sensitivity for both modalities decreased from the first to the second screening (DL: from 95% to 90%, p = 0.008; HG: from 74% to 57%, p < 0.001). At both the first and second screenings, the rate of false negatives for the DL was a fifth that of HG (0.5-0.6% vs. 2.9-3.2%). CONCLUSION: On 2-year longitudinal follow-up of a DR screening cohort, STDR prevalence decreased for both DL- and HG-based screening. Follow-up screenings in longitudinal DR screening can be more difficult and induce lower sensitivity for both DL and HG, though the false negative rate was substantially lower for DL. Our data may be useful for health-economics analyses of longitudinal screening settings.
format Online
Article
Text
id pubmed-7758133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77581332020-12-29 Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders Limwattanayingyong, Jirawut Nganthavee, Variya Seresirikachorn, Kasem Singalavanija, Tassapol Soonthornworasiri, Ngamphol Ruamviboonsuk, Varis Rao, Chetan Raman, Rajiv Grzybowski, Andrzej Schaekermann, Mike Peng, Lily H. Webster, Dale R. Semturs, Christopher Krause, Jonathan Sayres, Rory Hersch, Fred Tiwari, Richa Liu, Yun Ruamviboonsuk, Paisan J Diabetes Res Research Article OBJECTIVE: To evaluate diabetic retinopathy (DR) screening via deep learning (DL) and trained human graders (HG) in a longitudinal cohort, as case spectrum shifts based on treatment referral and new-onset DR. METHODS: We randomly selected patients with diabetes screened twice, two years apart within a nationwide screening program. The reference standard was established via adjudication by retina specialists. Each patient's color fundus photographs were graded, and a patient was considered as having sight-threatening DR (STDR) if the worse eye had severe nonproliferative DR, proliferative DR, or diabetic macular edema. We compared DR screening via two modalities: DL and HG. For each modality, we simulated treatment referral by excluding patients with detected STDR from the second screening using that modality. RESULTS: There were 5,738 patients (12.3% STDR) in the first screening. DL and HG captured different numbers of STDR cases, and after simulated referral and excluding ungradable cases, 4,148 and 4,263 patients remained in the second screening, respectively. The STDR prevalence at the second screening was 5.1% and 6.8% for DL- and HG-based screening, respectively. Along with the prevalence decrease, the sensitivity for both modalities decreased from the first to the second screening (DL: from 95% to 90%, p = 0.008; HG: from 74% to 57%, p < 0.001). At both the first and second screenings, the rate of false negatives for the DL was a fifth that of HG (0.5-0.6% vs. 2.9-3.2%). CONCLUSION: On 2-year longitudinal follow-up of a DR screening cohort, STDR prevalence decreased for both DL- and HG-based screening. Follow-up screenings in longitudinal DR screening can be more difficult and induce lower sensitivity for both DL and HG, though the false negative rate was substantially lower for DL. Our data may be useful for health-economics analyses of longitudinal screening settings. Hindawi 2020-12-15 /pmc/articles/PMC7758133/ /pubmed/33381600 http://dx.doi.org/10.1155/2020/8839376 Text en Copyright © 2020 Jirawut Limwattanayingyong et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Limwattanayingyong, Jirawut
Nganthavee, Variya
Seresirikachorn, Kasem
Singalavanija, Tassapol
Soonthornworasiri, Ngamphol
Ruamviboonsuk, Varis
Rao, Chetan
Raman, Rajiv
Grzybowski, Andrzej
Schaekermann, Mike
Peng, Lily H.
Webster, Dale R.
Semturs, Christopher
Krause, Jonathan
Sayres, Rory
Hersch, Fred
Tiwari, Richa
Liu, Yun
Ruamviboonsuk, Paisan
Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title_full Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title_fullStr Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title_full_unstemmed Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title_short Longitudinal Screening for Diabetic Retinopathy in a Nationwide Screening Program: Comparing Deep Learning and Human Graders
title_sort longitudinal screening for diabetic retinopathy in a nationwide screening program: comparing deep learning and human graders
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758133/
https://www.ncbi.nlm.nih.gov/pubmed/33381600
http://dx.doi.org/10.1155/2020/8839376
work_keys_str_mv AT limwattanayingyongjirawut longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT nganthaveevariya longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT seresirikachornkasem longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT singalavanijatassapol longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT soonthornworasiringamphol longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT ruamviboonsukvaris longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT raochetan longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT ramanrajiv longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT grzybowskiandrzej longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT schaekermannmike longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT penglilyh longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT websterdaler longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT semturschristopher longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT krausejonathan longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT sayresrory longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT herschfred longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT tiwariricha longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT liuyun longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders
AT ruamviboonsukpaisan longitudinalscreeningfordiabeticretinopathyinanationwidescreeningprogramcomparingdeeplearningandhumangraders